These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31847622)

  • 1. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors.
    Spugnini EP; Fais S
    Expert Opin Ther Pat; 2020 Jan; 30(1):15-25. PubMed ID: 31847622
    [No Abstract]   [Full Text] [Related]  

  • 2. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning of proton pump inhibitors in cancer therapy.
    Lu ZN; Tian B; Guo XL
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):925-937. PubMed ID: 28861639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor acidity, chemoresistance and proton pump inhibitors.
    De Milito A; Fais S
    Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells.
    Ihraiz WG; Ahram M; Bardaweel SK
    Acta Pharm; 2020 Jun; 70(2):179-190. PubMed ID: 31955147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy.
    Ikemura K; Hiramatsu S; Okuda M
    Front Pharmacol; 2017; 8():911. PubMed ID: 29311921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors may reduce tumour resistance.
    De Milito A; Fais S
    Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use.
    Numico G; Fusco V; Franco P; Roila F
    Crit Rev Oncol Hematol; 2017 Mar; 111():144-151. PubMed ID: 28259289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
    Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
    J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism.
    Fais S
    J Intern Med; 2010 May; 267(5):515-25. PubMed ID: 20433578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors for the treatment of cancer in companion animals.
    Walsh M; Fais S; Spugnini EP; Harguindey S; Abu Izneid T; Scacco L; Williams P; Allegrucci C; Rauch C; Omran Z
    J Exp Clin Cancer Res; 2015 Sep; 34(1):93. PubMed ID: 26337905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.
    Mottini C; Napolitano F; Li Z; Gao X; Cardone L
    Semin Cancer Biol; 2021 Jan; 68():59-74. PubMed ID: 31562957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).
    Kharkar PS
    Expert Opin Ther Pat; 2017 Jul; 27(7):753-761. PubMed ID: 28460551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect.
    Lugini L; Federici C; Borghi M; Azzarito T; Marino ML; Cesolini A; Spugnini EP; Fais S
    J Enzyme Inhib Med Chem; 2016 Aug; 31(4):538-45. PubMed ID: 26018420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitor pantoprazole inhibits the proliferation, self‑renewal and chemoresistance of gastric cancer stem cells via the EMT/β‑catenin pathways.
    Feng S; Zheng Z; Feng L; Yang L; Chen Z; Lin Y; Gao Y; Chen Y
    Oncol Rep; 2016 Dec; 36(6):3207-3214. PubMed ID: 27748935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nonmainstream approach against cancer.
    Fais S
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):882-9. PubMed ID: 26972280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.
    Yu M; Lee C; Wang M; Tannock IF
    Cancer Sci; 2015 Oct; 106(10):1438-47. PubMed ID: 26212113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity.
    Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF
    Cancer Chemother Pharmacol; 2017 May; 79(5):959-969. PubMed ID: 28378028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of extracellular acidity on resistance to chemotherapy treatment: a systematic review.
    da Silva VP; Mesquita CB; Nunes JS; de Bem Prunes B; Rados PV; Visioli F
    Med Oncol; 2018 Oct; 35(12):161. PubMed ID: 30377828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
    Ahmed ZSO; Golovoy M; Abdullah Y; Ahmed RSI; Dou QP
    Recent Pat Anticancer Drug Discov; 2021; 16(2):161-186. PubMed ID: 34132186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.